Peer-influenced content. Sources you trust. No registration required. This is HCN.
Cancer Therapy Advisor
In the realm of HER2-positive early breast cancer, achieving a pathological complete response (pCR) post-neoadjuvant therapy has been linked to a markedly reduced risk of recurrence, highlighting the critical role of tailored treatment strategies in improving patient outcomes.
Oncology, Medical February 5th 2024
Oncology Learning Network
Highlighting a paradigm shift in breast cancer treatment, the NRG Oncology/NSABP B-51/RTOG 1304 study demonstrates that certain patients with node-negative breast cancer post-neoadjuvant chemotherapy may safely omit adjuvant regional nodal irradiation, challenging conventional treatment approaches and potentially improving patient quality of life.
Oncology, Medical January 8th 2024
The New England Journal of Medicine
The study underscores the potential of perioperative durvalumab in combination with neoadjuvant chemotherapy to significantly improve event-free survival and pathological complete response in patients with resectable NSCLC.
Oncology, Medical November 6th 2023
Discover how pre-surgery treatment with T-VEC can significantly improve long-term survival rates in advanced melanoma patients, as revealed in a recent phase 2 trial.
Dermatology October 2nd 2023
Renal & Urology News
New data suggests that intensifying neoadjuvant therapy with abiraterone or docetaxel could significantly improve outcomes in very high-risk prostate cancer patients. Explore the full findings to consider how this could impact your treatment approach.
Oncology, Medical September 19th 2023
Explore the latest findings from the VESPER trial that suggest a promising shift in bladder cancer treatment strategy, potentially setting a new standard for neoadjuvant therapy.
Oncology, Medical June 20th 2023